ESCRS - PP11.10 - Transepithelial Iontophoresis-Assisted Cross Linking For Progressive Keratoconus: Up To 7 Years Of Follow Up

Transepithelial Iontophoresis-Assisted Cross Linking For Progressive Keratoconus: Up To 7 Years Of Follow Up

Published 2022 - 40th Congress of the ESCRS

Reference: PP11.10 | Type: Free paper | DOI: 10.82333/7zc1-s287

Authors: Riccardo Vinciguerra* 1

1Humanitas San Pio X Hospital, Milan, Italy,Milan,Italy

Purpose

In this article we aim to report long-term clinical results of transepithelial cross-linking with Iontophoresis (I-CXL) for progressive keratoconus (KC).

Setting

Humanitas Clinical and Research Center

Methods

Nineteen eyes of 19 patients treated with I-CXL were included. Preoperatively and in all available follow ups the following parameters were measured. Corrected distance visual acuity (CDVA), refraction, corneal topography and aberrometry (Costruzione Strumenti Oftalmici, Florence, Italy), tomography (OCULUS; Wetzlar, Germany). Definition of progression was 2/3 criteria of the following: increase of “A” value, increase of “B” value, decrease of minimal thickness evaluated with the ABCD progression display above 95% confidence interval for post-CXL population when compared to the scan 12 months post-op.

Results

The mean follow-up time of included patients was 63 months (range 12 to 84 months). The general linear model showed no significant change over time in CDVA, Maximum Keratometry, Thinnest point, and A, B, C values of the Belin Progression Display (p>0.05). Conversely, comatic and high order aberrations decreased significantly over time (both p=<0.001). Five cases (26.31%) showed significant progression after a mean of 55 months (range 36-72).

Conclusions

Our study shows the ability of I-CXL to slow down KC progression in the majority of included patients with a 26% progression rate